Revance Therapeutics Inc (RVNC),这家致力于开发新型抗皱注射剂的公司,周二夜盘股价大跌16.9%,收于4.80美元,主要受两大消息影响。
首先,Revance宣布撤回之前提供的全年业绩指引,不再给出任何前瞻性指导,这引发了市场对公司未来增长前景的担忧。作为一家尚未实现盈利的生物科技公司,投资者往往依赖于管理层提供的业绩预测,用以评估公司的发展潜力。此次预测指引的撤回使RVNC在业内地位面临挑战。
另一方面,RVNC与Crown Labs的合并交易也出现延迟。双方同意将要约收购的最后期限延长至11月12日。长期拖延的并购交易令人质疑交易能否最终完成,进一步打击了投资者的信心。值得注意的是,RVNC股价在过去一段时间内已累积下跌超过32%,持续的下滑走势更加剧了市场对公司前景的担忧。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.